Skip to content

Assessment of excess bacterial growth in the small intestine among patients with Inflammatory Bowel Disease (IBD)

Small intestinal bacterial overgrowth in inflammatory bowel disease - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087006
Enrollment
105
Registered
2025-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K508- Crohns disease of both small andlarge intestine Health Condition 2: K510- Ulcerative (chronic) pancolitis

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

MANDAPATI C S PRAVEEN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All newly diagnosed and existing patients, aged more than 18 years, regardless of disease activity who are diagnosed to have Inflammatory bowel disease, based on clinical presentation, endoscopic, imaging, and histological features based on the criteria by Indian society of gastroenterology

Exclusion criteria

Exclusion criteria: Patients with acute bacterial gastrointestinal infections in the last 1 month Patients with use of antibiotics, probiotics, Proton pump inhibitors, anti-diarrheal drugs such as loperamide, laxatives, anticholinergics known to affect orocecal transit time like dicyclomine and hyoscyamine within 1 month prior to the breath test. Pregnancy

Design outcomes

Primary

MeasureTime frame
The frequency of SIBO in patients with IBD with a glucose hydrogen breath testTimepoint: Glucose hydrogen breath test at the baseline or Day 1. No follow up.

Secondary

MeasureTime frame
To correlate the presence of SIBO with various factors such as social demographics, biochemical parameters, type of IBD and severity of IBDTimepoint: 18 months

Countries

India

Contacts

Public ContactMANDAPATI C S PRAVEEN

Kasturba Medical College, Manipal

praveenmcs19@gmail.com8008339929

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026